The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
Explore more
A scientific statement regarding sex differences in patients with peripheral vascular disease has been published by the AHA.
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
COLUMBIA SC (WOLO) – We all understand the importance of the heart, but there are some other afflictions related to the ...
Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery ...